Transgender hormone therapy , also sometimes called cross-sex hormone therapy , is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is feminization or masculinization :. Some intersex people may also undergo hormone therapy, either starting in childhood to confirm the sex they were assigned at birth , or later in order to align their sex with their gender identity. Non-binary or genderqueer people may also undergo hormone therapy in order to achieve a desired balance of sex hormones.
Cross-Sex Hormone Therapy: What Are the Long-Term Risk Factors?
Effects of Cross-Sex Hormone Treatment on Transgender Women : Obstetrics & Gynecology
Colleague's E-mail is Invalid. Your message has been successfully sent to your colleague. Save my selection. Body mass index, BP, lipids, and sex hormone levels were measured at baseline and 6 months. Persistence of menses at 6 months in transgender men was recorded. Baseline and 6-month median BPs and lipid values were within a normal clinical range.
Effects of Cross-Sex Hormone Treatment on Transgender Women and Men
To describe weight, body mass index, blood pressure, lipids, and hormone levels in transgender women and men presenting for initiation of cross-sex hormone therapy at a community clinic in the United States. Twenty three transgender women persons assigned male at birth who identify as women and want to use estrogen to develop female secondary sex characteristics and 34 transgender men persons assigned female at birth who identify as women and want to use testosterone to develop male secondary sex characteristics presenting for initiation of hormone therapy at a community health center were enrolled. Body mass index, blood pressure, lipids, and sex hormone levels were measured at baseline and 6 months. Persistence of menses at 6 months in transgender men was recorded.
Transgender individuals experience discord between their self-identified gender and biological sex. Transgender men are individuals who were assigned female at birth but identify as men, and transgender women are individuals who were assigned male at birth but identify as women. While research in this area is sparse, the current evidence points toward a biologic etiology for transgenderism. These data come from studies examining children with congenital genitourinary anomalies who were assigned gender at birth 1 , 2 , as well as postmortem cadaveric studies 3.